Proximal muscular atrophy and weakness: An unusual adverse effect of deferasirox iron chelation therapydoi:10.1016/j.nmd.2016.02.011Beta-thalassemiamajorIronchelationtherapyAdverseeffectsMuscularweaknessDeferasiroxDeferasirox is a standard treatment for chronic transfusional iron overload. Adverse effects of ...
In the early 2000s public interest in chelation therapy coerced politicians to pressure the NIH to investigate the treatment. Leadership in the American College for the Advancement of Medicine (ACAM) and other associations led to the National Heart, Lung, and Blood Institute to set up...
Eiseman JL, Alvares AP. Heme metabolism in the fetoplacental unit and neonatal livers during lactation: effect of gold sodium thiomalate. Journal of Pharmacology and Experimental Therapeutics 214: 250–256, 1980 PubMedCASGoogle Scholar Evans RB, Ettensohn DB, Fawaz-Estrup F, Lally EV, Kaplan SR...
Tsironi, Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine, Int. J. Hematol. 86 (3) (2007) 212-215.Aessopos A, Kati M, Farmakis D, Polonifi E, Deftereos S, Tsironi M. Intensive chelation therapy in β-thalassemia and possible ...
A serial follow-up of serum ferritin level and judicious iron chelation therapy will be needed to manage the side effect of iron overload in RIST and improve transplantation outcomes.Kim YRKim JSCheong JWSong JWMin YHActa HaematologicaTransfusion-associated iron overload as an adverse risk factor...
ADE/ADRs report and DDIs. Conclusions: The impact of ADE/ADRs in ESRD patients should be always considered. Guidelines as well as continuous training in the context of evidence-based clinical practice by healthcare personnel on therapy administration and prevention of adverse events are important. ...